Osimertinib maintenance therapy for treating stage III unresectable EGFR mutation positive non-small-cell lung cancer after definitive platinum-based chemoradiation therapy

Osimertinib is in development for the treatment of stage III, unresectable EGFR mutation positive non-small cell lung cancer (NSCLC) following definitive chemoradiation therapy. NSCLC is the most common form of lung cancer. Stage III lung cancer means the cancer is in more than one lobe of the lung, or it has spread to lymph nodes or nearby structures in the chest. EGFR is a protein on cells that helps them grow. A mutation in the gene for EGFR can make it grow too much, which can cause cancer. Smoking tobacco is the cause of most lung cancers and the biggest risk factor. Other risk factors include second-hand smoke, exposure to workplace carcinogens, radiation exposure, environmental pollution, and family history of lung cancer. There are currently no approved treatment options for the maintenance treatment of stage III, unresectable EGFR mutation positive NSCLC following chemoradiation therapy